Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
3(75.0%)
Phase 3
1(25.0%)
4Total
Phase 2(3)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06700603Phase 2Not Yet Recruiting

Second-line Irinotecan Liposome Combination Regimen for Irinotecan-treated Pancreatic Cancer

Role: lead

NCT06501664Phase 3Not Yet Recruiting

Liposomal Irinotecan and 5-FU as Second-line Therapy for Patients With ESCC

Role: lead

NCT06487702Phase 2Not Yet Recruiting

A Phase lb/lI Clinical Study in Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Role: lead

NCT06329947Phase 2Not Yet Recruiting

A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRAD

Role: lead

All 4 trials loaded